Forming Alliances to forge ahead

SIRO Clinpharm and RegRx Consulting, LLC

Alliance provides solutions related to US drug regulatory solutions for pharmaceutical companies

RegRx Consulting, LLC is a select group of highly skilled regulatory affairs professionals with over 50 years of combined experience with the US FDA (CDER/CBER) and other regulatory authorities. They provide consulting services and solutions to US and foreign pharmaceutical companies who need assistance with development and commercial drug regulatory affairs.

They handle Overall regulatory development strategy, maintaining INDs and NDAs, due diligence from the array of services. They have handled multiple Regulatory Applications pertaining to NDA, IND, CTDs, CTA and ANDA.

SIRO Clinpharm and Virginia Contract Research Organization

Pact enables SIRO’s clients access to booming Taiwan clinical research market

VCRO is one of the most experienced CROs with the longest history in Taiwan’s contract research sector. VCRO is dedicated to offering full range ICH-GCP compliant clinical research services including EDC, IVRS and analytical laboratory services for pharmaceutical and biotech companies. They have an extensive network in the Asia-Pacific regions of Japan, China, Singapore and Hong Kong.

This alliance is a collaborative partnership and will help us deliver value arising out of clinical capabilities and wider geographies to our global set of clients.

SIRO Clinpharm and DreamCIS

Pact will broaden SIRO’s reach in Asian Clinical trials sector

DreamCIS is a South Korea based CRO with close to a decade’s experience in offering clinical research services to pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. Their services range includes Clinical trial management, Pharmacovigilance, Post Marketing Surveillance (PMS), Data management, Biostatistics and Quality Assurance services.

This partnership is ideally created to provide a sustainable value for our existing as well as potential customers in the rapidly growing Korean clinical trials market.